CD108
- Known as:
- CD108
- Catalog number:
- 11-275-C100
- Product Quantity:
- 0.1 mg
- Category:
- -
- Supplier:
- Exbio
- Gene target:
- CD108
Related genes to: CD108
- Gene:
- SEMA7A NIH gene
- Name:
- semaphorin 7A (John Milton Hagen blood group)
- Previous symbol:
- SEMAL
- Synonyms:
- H-Sema-L, CD108
- Chromosome:
- 15q24.1
- Locus Type:
- gene with protein product
- Date approved:
- 1999-06-25
- Date modifiied:
- 2019-04-23
Related products to: CD108
Antibodies: Mouse Monoclonal to CD108 _ Semaphorin 7a, Species Reactivity: Human, Clone: MEM-150, Isotype: IgMAntibodies: Mouse Monoclonal to CD108 _ Semaphorin 7a, Species Reactivity: Human, Clone: MEM-150, Isotype: IgMAntibodies: Mouse Monoclonal to CD108 _ Semaphorin 7a, Species Reactivity: Human, Clone: MEM-150, Isotype: IgMAntibodies: Mouse Monoclonal to CD108 _ Semaphorin 7a, Species Reactivity: Human, Clone: MEM-150, Isotype: IgMAntibodies: Mouse Monoclonal to CD108 _ Semaphorin 7a, Species Reactivity: Human, Clone: MEM-150, Isotype: IgMAntibodies: Mouse Monoclonal to CD108 _ Semaphorin 7a, Species Reactivity: Human, Clone: MEM-150, Isotype: IgMCD108 SEMA7A antibody Ab host: GoatCD108 SEMA7A IgG2b antibody Ab host: RatCD108 SEMA7A IgM antibody Ab host: MouseCD108 SEMA7A IgM antibody Ab host: MouseCD108 SEMA7A IgM antibody Ab host: MouseCD108 / SEMA7A antibody Host GoatCD108 / SEMA7A antibody Host RabbitCD108 / SEMA7A Clone 'MEM-150 antibody Isotype IgM Host MouseCD108 / SEMA7A Clone 'MEM-150 antibody Isotype IgM Host Mouse Related articles to: CD108
- - Source: PubMed
Trivigno Silvia Maria GraziaMangin Pierre - Macrophage-associated responses at sites of nerve injury are involved in the initiation and persistence of neuropathic pain (NP). Immune semaphorins (SEMAs), including SEMA3A, SEMA3E, SEMA4A, SEMA4D, and SEMA7A, regulate macrophage migration and activation, but their roles in NP remain unclear. This study aimed to identify immune SEMAs associated with NP by analyzing their serum levels and expression in sensory nerve tissues of patients with NP, and to evaluate the potential effects of SEMA-targeted intervention in a mouse model. - Source: PubMed
Publication date: 2026/08/02
Yoshidomi SatoFujii TakayukiHonda HiroyukiKashu Kaoru YoshidaMiyachi YukinoInoue YukaOgata HidenoriYamasaki RyoIwaki ToruIsobe Noriko - The pathogenesis of multiple sclerosis (MS) remains incompletely elucidated. Semaphorins play an active role in the immune and nervous systems by regulating receptor-mediated adhesion mechanisms. Immunosemaphorins have recently emerged as diagnostic biomarkers or therapeutic targets in MS. - Source: PubMed
Publication date: 2026/07/14
Sarıdaş FurkanAydın BirnurÖzpar RifatKoç Emine RabiaHakyemez BahattinAlkan TülinTuran Ömer Faruk - Ovarian cancer (OC) is the third most aggressive gynecological malignancy worldwide, and platinum resistance is a common malignant feature of OC associated with poor clinical prognosis. Circular RNA (circRNA) has been reported in many tumor progressions, including drug resistance. In this study, a new circRNA that mediates OC progression by acting as a ceRNA was identified. - Source: PubMed
Publication date: 2026/07/23
Niu ZhiyuanMo YuqingYang BikangZhang MojianZhong RuiZhang ShufangYang ShengPeng Shuping - The roles of mitochondrial genes in the development of thyroid cancer (TC) and the associated tumor microenvironment remain to be elucidated. Based on 64 dysregulated mitochondrial genes, unsupervised consensus clustering analysis was performed using TC datasets from The Cancer Genome Atlas and integrated gene expression databases. A dysregulated mitochondrial-based prognostic model was constructed using machine learning. Fourteen prognostic genes were identified, and the correlation between semaphorin 7A (SEMA7A) and immune cell infiltration was validated. The functions of SEMA7A were investigated through plate cloning, scratch wound healing, and Transwell invasion assays. This study constructed a prognostic model for predicting overall survival by identifying 14 mitochondrial dysregulated-based prognostic genes (APOD, ATP2C2, FAM111B, GJB4, GZMA, HHIPL2, IFIT3, IL18, MCEMP1, PRRT4, RGS16, SEMA7A, SLC2A3, and TDRD9). Its effectiveness was validated in an independent cohort. The model accurately predicted OS across cancer stages. SEMA7A expression was significantly upregulated in papillary thyroid carcinoma (PTC) tissues and PTC cell lines. Functional experiments showed that SEMA7A promoted TC progression, including cell proliferation, migration, and invasion. Compared with the SEMA7A low-expression group, the high-expression group showed a larger FOXP3+ regulatory T cell (Treg) population. Although a higher ratio of SEMA7A + CD8-positive cells/SEMA7A + FOXP3-positive cells was observed, increased Treg abundance is known to shift the immune context toward a less cytotoxic and more exhausted state. Thus, oncogenic SEMA7A in TC promotes malignant functions in TC cells and may play an important role in shaping the immunosuppressive microenvironment. Consequently, our mitochondrial dysregulation-based prognostic risk model for TC may offer good clinical application value. - Source: PubMed
Zha WeinaLi JingwuLi YufengLi HanchenYang XiaolinLiu YingWang ChenXu YiLi XingchenWang XueLiu Geling